March 20, 2026

The need-to-know this morning

U.K. health officials reopened a review of two Alzheimer's therapies — Eli Lilly's Kisunla and Eisai and Biogen's Leqembi — after previously finding they did not provide good therapeutic value for how much they cost.
Novartis said it is buying an experimental breast cancer drug from Delaware-based Synnovation Therapeutics for $2 billion upfront.
Rhythm Pharmaceuticals won expanded FDA approval for its drug Imcivree to treat acquired hypothalamic obesity, a rare disease characterized by accelerated and sustained weight gain caused by damage to the hypothalamus.

stat summit

Medicare chief frames TrumpRx as a limited tool

Chris Klomp, a senior HHS official, offered a notably restrained view of TrumpRx while speaking at the STAT Breakthrough Summit East yesterday. Although President Trump described the prescription drug platform "as transformative," Klomp framed it instead as a limited, cash-pay tool rather than a systemwide fix for drug pricing.

"The goal was not actually some massive reach," Klomp said.

That said, the platform has shown lower prices for GLP-1s and fertility drugs, which often aren't covered by health insurance, Klomp said.

Klomp also pointed to broader administration priorities like Medicare savings, interoperability, and prior authorization reform. He acknowledged that ongoing FDA personnel turnover, particularly as the agency pushes faster reviews and looser evidentiary standards, is worrisome.

"Trust is generally earned over time, and it's hard fought through battles," Klomp said. "It takes a long time to build and it's very easy to destroy."

glp-1 drugs

High-dose Wegovy gets FDA nod

Novo Nordisk secured FDA approval for a higher dose of its obesity drug Wegovy, thanks to the new priority voucher program tied to its pricing agreement with the Trump administration, STAT's Elaine Chen writes. The initiative gave the 7.2 mg version a faster route to market as Novo tries to close ground on Eli Lilly.

The added efficacy is meaningful but not game-changing — studies show 18.7% weight loss versus roughly 15% on the standard dose. This is still shy of the 21% seen with Lilly's Zepbound — suggesting this is more about narrowing the gap than retaking the lead. Novo plans to launch the high-dose Wegovy in April, but hasn't yet disclosed its price.

stat summit

China's biotech surge is challenging U.S. dominance

If the U.S. wants to stay on top in biotech, it may need to borrow a few ideas from China:

"CAR-T cells were born in the U.S., actually here in New York City, but today there are more CAR-T cell trials in China than in the U.S.," Michel Sadelain of Memorial Sloan Kettering said at the STAT Breakthrough Summit East. "They're variants on things that often have been published here before, but boom, the trial starts there and then they have patient data, while here we're still thinking about how to find money to perform a trial."

This is due in part to a dual-track regulatory system in China that allows faster, less bureaucratic studies, STAT's Megan Molteni writes. That speed translates into earlier human data. U.S. researchers, meanwhile, are struggling to secure funding and navigate regulatory hurdles.

philanthropy

Stanley family funds new psychiatric research

The Stanley Family Foundation is deepening its long-running bet on the Broad Institute, pushing its total giving past $1 billion with a new $280 million gift aimed at research on bipolar disorder and schizophrenia. The two conditions still have an enormous unmet need, and there's still frustratingly little clarity in how they work.

The funding comes at a moment when federal research support feels unstable, giving Broad scientists the rare luxury of taking real risks in early-stage genomic work, from sequencing patient DNA to mapping how certain variants drive disease.

The backstory is personal: Jonathan Stanley's severe bipolar episode in his youth catalyzed a decades-long philanthropic mission by his parents to crack the biology of psychiatric illness. The result is one of the most heavily resourced efforts in the field, built on the premise that understanding genetic roots is the only credible path to better drugs — especially when mainstays like lithium still work more by accident than design.

More around STAT